tirzepatide cardiovascular outcomes trial Risk of major adverse events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Cardiorenal Outcomes With Tirzepatide Compared

Symptoms of Poor Healing: Slow closure of wounds, formation of thick, keloid, or hypertrophic scars, and persistent tenderness

Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study

The American Diabetes Association (ADA) Standards of Care emphasize that diabetes is a progressive condition requiring ongoing pharmacological management in most patients, and discontinuing effective therapy typically results in deterioration of glycemic control

Until then, medications like Wegovy and Zepbound remain the best-studied and most accessible choicesand for many people, they already deliver meaningful, sustainable results